Company Overview
Souffle Therapeutics is an RNA therapeutics company developing its REMEDY platform to deliver oligonucleotide therapies to specific cell types outside the liver.
Latest Funding Signal
$135M
Soufflé Therapeutics Raises $135M Series B to Advance RNA Delivery Platform
Lead Investors
Juvia Group
Other Investors
TCG Crossover Management, BB Biotech, Fidelity Management & Research, Balyasny Asset Management, Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek, Vida Ventures
Use of Funds
The funding will advance Souffle’s first three RNA-delivery programs toward the clinic and support continued pipeline progress.